Repligen (NASDAQ: RGEN) reported Q4 EPS of $0.07, in-line with the analyst estimate of $0.07. Revenue for the quarter came in at $21.4 million versus the consensus estimate of $19.84 million.

Tony J. Hunt, President and Chief Executive Officer said, “2015 was a great year for Repligen, as we executed on our growth strategy and established the Repligen brand in key bioprocessing end-markets, while delivering strong financial performance across all of our product lines. For the year, we reported exceptional product sales growth and margin expansion. We finished the year with fourth quarter revenue ahead of our expectations, led by an outstanding quarter for ATF and strong adoption of our growth factors. As we look to 2016, we expect another double-digit growth year driven by healthy end-markets, accelerating brand recognition and continued adoption of our innovative portfolio of bioprocessing products.”

For earnings history and earnings-related data on Repligen (RGEN) click here.